Prevalence and risk factors of chemotherapy-induced oral mucositis among adult cancer patients at the cancer unit of Mbarara Regional Referral Hospital

IF 1.4 4区医学 Q4 ONCOLOGY

Asia-Pacific journal of clinical oncology Pub Date : 2023-12-26 DOI:10.1111/ajco.14044

Fredrick Atwiine, Julius Kyomya, Esther C. Atukunda, John Isiiko, Tadele Mekuriya Yadesa

{"title":"Prevalence and risk factors of chemotherapy-induced oral mucositis among adult cancer patients at the cancer unit of Mbarara Regional Referral Hospital","authors":"Fredrick Atwiine, Julius Kyomya, Esther C. Atukunda, John Isiiko, Tadele Mekuriya Yadesa","doi":"10.1111/ajco.14044","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Chemotherapy is a common treatment for cancer, but it is associated with adverse drug reactions like oral mucositis. This condition destroys basal cells in the oral mucosal layer, causing inflammation and ulceration. This can impact the patient's physical, emotional, and psychological well-being, affecting treatment outcomes and quality of life. This study aims to determine the prevalence, severity, and risk factors of chemotherapy-induced oral mucositis among adult cancer patients.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The study was a cross-sectional study conducted among adult cancer patients receiving chemotherapy at the cancer unit of Mbarara Regional Referral Hospital in southwestern Uganda. Data was collected through patient interviews, oral examinations, and patient chart reviews.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Out of 268 patients, 115 (42.9%) experienced oral mucositis. Grade 2 oral mucositis was the most common (44.3%) followed by grade 1 (35.7%) and grade 3 (20.0%). Independent risk factors of chemotherapy-induced oral mucositis were female gender (Adjusted Odds Ratio (AOR) = 2.19, 95% confidence interval [CI]: 1.27–3.78; <i>p</i>-value = 0.005), poor oral hygiene (AOR = 3.70, 95% CI: 1.51–9.10; <i>p</i>-value = 0.04), and receiving chemotherapy containing an alkylating agent (AOR = 3.17, 95% CI: 1.63–6.19; <i>p</i>-value < 0.001).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The study found that two out of five chemotherapy patients developed oral mucositis, with nearly half being grade 2. The risk factors identified in our study were comparable to those reported in previous studies. Therefore, identification and assessment of cancer patients at high risk for chemotherapy-induced oral mucositis should be routinely done for proper and timely management.</p>\n </section>\n </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajco.14044","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Chemotherapy is a common treatment for cancer, but it is associated with adverse drug reactions like oral mucositis. This condition destroys basal cells in the oral mucosal layer, causing inflammation and ulceration. This can impact the patient's physical, emotional, and psychological well-being, affecting treatment outcomes and quality of life. This study aims to determine the prevalence, severity, and risk factors of chemotherapy-induced oral mucositis among adult cancer patients.

Methods

The study was a cross-sectional study conducted among adult cancer patients receiving chemotherapy at the cancer unit of Mbarara Regional Referral Hospital in southwestern Uganda. Data was collected through patient interviews, oral examinations, and patient chart reviews.

Results

Out of 268 patients, 115 (42.9%) experienced oral mucositis. Grade 2 oral mucositis was the most common (44.3%) followed by grade 1 (35.7%) and grade 3 (20.0%). Independent risk factors of chemotherapy-induced oral mucositis were female gender (Adjusted Odds Ratio (AOR) = 2.19, 95% confidence interval [CI]: 1.27–3.78; p-value = 0.005), poor oral hygiene (AOR = 3.70, 95% CI: 1.51–9.10; p-value = 0.04), and receiving chemotherapy containing an alkylating agent (AOR = 3.17, 95% CI: 1.63–6.19; p-value < 0.001).

Conclusion

The study found that two out of five chemotherapy patients developed oral mucositis, with nearly half being grade 2. The risk factors identified in our study were comparable to those reported in previous studies. Therefore, identification and assessment of cancer patients at high risk for chemotherapy-induced oral mucositis should be routinely done for proper and timely management.

Abstract Image

查看原文本刊更多论文

姆巴拉拉地区转诊医院（Mbarara Regional Referral Hospital）癌症科成年癌症患者化疗引发口腔黏膜炎的患病率和风险因素。

背景：化疗是一种常见的癌症治疗方法，但与口腔黏膜炎等药物不良反应有关。这种情况会破坏口腔黏膜层的基底细胞，引起炎症和溃疡。这会影响患者的身体、情绪和心理健康，影响治疗效果和生活质量。本研究旨在确定化疗引起的口腔黏膜炎在成年癌症患者中的发病率、严重程度和风险因素：本研究是一项横断面研究，对象是在乌干达西南部姆巴拉拉地区转诊医院癌症科接受化疗的成年癌症患者。数据通过患者访谈、口腔检查和病历审查收集：在 268 名患者中，115 人（42.9%）出现了口腔黏膜炎。2级口腔黏膜炎最常见（44.3%），其次是1级（35.7%）和3级（20.0%）。化疗诱发口腔黏膜炎的独立风险因素是女性（调整后比值比 (AOR) = 2.19，95% 置信区间 [CI]：1.27-3.78；p 值 = 0.005）、口腔卫生差（AOR = 3.70，95% CI：1.51-9.10；p 值 = 0.04）以及接受含有烷化剂的化疗（AOR = 3.17，95% CI：1.63-6.19；p 值研究发现，每五名化疗患者中就有两名出现口腔黏膜炎，其中近一半为二级。我们的研究发现的风险因素与以往研究报告的风险因素相当。因此，应定期对化疗诱发口腔黏膜炎的高危癌症患者进行识别和评估，以便及时采取适当的治疗措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asia-Pacific journal of clinical oncology 医学-肿瘤学

CiteScore

3.40

自引率

0.00%

发文量

175

审稿时长

6-12 weeks

期刊介绍： Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.